Navigation Links
American Medical Systems and Allergan Sign Agreement for JetTouch™/BOTOX® Co-Development Program
Date:6/7/2012

CHADDS FORD, Pa., June 7, 2012 /PRNewswire-FirstCall/ -- American Medical Systems (AMS), an Endo Health Solutions company (Nasdaq: ENDP), announced today it has signed a co-development agreement with Allergan, Inc. to jointly develop and seek regulatory approval for the delivery of BOTOX®  (onabotulinumtoxinA)  using the JetTouch™ system for treatment of overactive bladder (OAB).

AMS' JetTouch™ is a novel injection platform that has the potential to enable needle-free injection into any area of the body reachable by endoscopic or percutaneous access. Needle-free injection with the JetTouch™ system is being evaluated as an innovative means for local drug delivery and may provide treatment administration efficiencies for the physician. 

BOTOX® was approved by the U.S. Food and Drug Administration (FDA) in August 2011 for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (e.g. spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an anticholinergic medication. BOTOX® is currently under FDA review as a potential treatment for OAB with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to or are intolerant of an anticholinergic medication.

"Endo Health Solutions continues to focus on expanding its therapeutic offerings in urology and exploring innovative options for patients," said Dr. Ivan Gergel, Executive Vice President of R&D and Chief Scientific Officer of Endo Health Solutions. "With AMS' position in the urology marketplace, the potential of the JetTouch™ system combined with the delivery of BOTOX® make this a mutually beneficial business opportunity."

Under the co-development agreement, AMS will first develop JetTouch™ for general use in the bladder. Subject to the FDA approval of BOTOX® for injection by needle as a treatment for OAB, AMS, in collaboration with Allergan, will seek to add BOTOX® to the JetTouch™ label, and Allergan plans to seek regulatory advice to add the delivery of BOTOX® with JetTouch™ to the BOTOX® label. 

About American Medical Systems
American Medical Systems, headquartered in Minnetonka, Minnesota, is a diversified supplier of medical devices and procedures to treat incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women. These disorders can significantly diminish one's quality of life and profoundly affect social relationships. In recent years, the number of people seeking treatment has increased markedly as a result of longer lives, higher-quality-of-life expectations and greater awareness of new treatment alternatives. American Medical Systems' products reduce or eliminate the incapacitating effects of these diseases, often through minimally invasive therapies. The Company's products were used to treat approximately 340,000 patients in 2010. AMS is part of Endo Health Solutions Inc. (Nasdaq: ENDP), a diversified healthcare company that is dedicated to improving care through a combination of branded products, generics, devices, technology and services. (http://www.endo.com).

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

BOTOX is a registered trademark of Allergan, Inc.


'/>"/>
SOURCE Endo Health Solutions Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE
2. Attack on the Website of the American Pharmacists Association
3. American Society of Hematology Statement on House Passage of Prescription Drug User Fee Act (PDUFA)
4. COPD Tops Asthma as the Focus Indication for Next Generation Respiratory Therapies at the 2012 American Thoracic Society Conference
5. Novocure™ to Present NovoTTF™ Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology
6. EQUICARE CS Cancer Survivorship Case Management Software Listed as a "Best Practices" Resource by the American College of Surgeons Commission on Cancer (COC)
7. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. American Society of Hematology Statement on Senate Passage of Prescription Drug User Fee Act (PDUFA)
9. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
10. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
11. Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
(Date:12/2/2016)... -- bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, ... von Kenia eingeführt. Continue Reading ... ... (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde durch die Clinton ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... edition of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic ... health while maintaining fulfilling lives. “We are prolonging life 6 years in the ...
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... San Francisco, CA (PRWEB) , ... December 02, ... ... in digitally-enabled care journeys, announced today that it has raised $6.0 million in ... are inspired by Clarify Health’s conviction that patients and their caregivers can receive ...
(Date:12/2/2016)... ... 2016 , ... ‘Tis the season for giving! Today, 20 creative teams across ... Partnership and the Drug Enforcement Administration as part of the National Red Ribbon Week ... schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. Be ...
(Date:11/30/2016)... ... 30, 2016 , ... Standard Process, Inc. is proud to ... recognition of the largest closely held companies headquartered in Wisconsin. This marks the ... Standard Process was awarded the Talent Award for providing outstanding employee benefits. ...
Breaking Medicine News(10 mins):